Dulaglutide,
does it really help with Lower HbA1c in type 2 diabetes and reduce major adverse cardiovascular events in people at high cardiovascular risk?
research showsDulaglutide is rated B with 72 points. Large randomized evidence shows that it lowers HbA1c in type 2 diabetes and reduces major adverse cardiovascular events in people with cardiovascular disease or risk factors, but the MACE claim rests on the single REWIND trial and both cited trials were funded by Eli Lilly, so replication by different investigators and funders is not confirmed and the axis 2 R1 ceiling of B applies. In REWIND, 9,901 participants followed for a median of 5.4 years had MACE rates of 12.0% versus 13.4%, HR 0.88 (95% CI 0.79 to 0.99; P=0.026). AWARD trials and long-term REWIND analyses consistently confirmed HbA1c lowering. Gastrointestinal adverse effects and risks involving pancreatitis, gallbladder disease, or hypoglycaemia with concomitant therapy are recorded separately under safety.
ads claimMarketing can simplify the medicine into one injection that solves glucose, weight, and cardiovascular risk simultaneously. In practice it is prescription therapy used with diet and exercise; absolute cardiovascular benefit depends on baseline risk, and weight loss is not the core endpoint of this combined claim.
Useful facts when choosing a product
- Dulaglutide is a prescription GLP-1 receptor agonist injected subcutaneously once weekly, and dose selection or escalation should follow the approved label and prescriber instructions.
- The REWIND cardiovascular evidence applies most directly to adults with type 2 diabetes who have established cardiovascular disease or cardiovascular risk factors.
- Nausea, vomiting, diarrhoea, and reduced appetite are common, and severe persistent abdominal pain can require assessment for pancreatitis or gallbladder disease.
- Concomitant insulin or a sulfonylurea can increase hypoglycaemia risk, and the product label should be checked for the rodent thyroid C-cell tumour warning and related contraindications or precautions.
What the research actually shows
REWIND randomized 9,901 participants at 371 sites in 24 countries to dulaglutide 1.5 mg weekly or placebo. Over a median of 5.4 years, first MACE occurred in 594 of 4,949 versus 663 of 4,952 participants, giving HR 0.88. Long-term REWIND analyses found HbA1c lowering across baseline glycaemic ranges, and the 810-participant, 78-week AWARD-2 trial found greater HbA1c reduction with dulaglutide 1.5 mg than with insulin glargine without forced titration. Weight loss was also observed but is secondary to the HbA1c and MACE claim assessed here.
Why this is classified as B (72)
The 9,901-participant REWIND double-blind cardiovascular outcomes trial established superiority on MACE, HR 0.88 (95% CI 0.79 to 0.99; P=0.026), over a median of 5.4 years, and HbA1c lowering was repeated across AWARD trials and long-term REWIND analyses. However, REWIND is the only trial of the MACE claim, and the cited REWIND and AWARD-2 trials were both funded by Eli Lilly, so replication by different investigators and funders is not confirmed and the axis 2 R1 ceiling of B applies. As a large hard-endpoint RCT of a prescription drug, the axis 3 ceiling for manufacturer funding is not applied. The result is B with 72 points.
Counterpoint. The B efficacy grade does not guarantee the same absolute benefit or safety for every patient. Gastrointestinal tolerance, concomitant medicines, dehydration-related renal risk, pancreatic or gallbladder history, and medullary-thyroid-cancer-related contraindications require individual assessment.
Rejudgment record. New verdict — Reflected prespecified superiority on the direct hard MACE endpoint in the 9,901-participant REWIND trial over a median of 5.4 years (HR 0.88, P=0.026) and repeated HbA1c lowering in AWARD trials; because the MACE claim rests on REWIND alone and both cited trials (REWIND, AWARD-2) were funded by Eli Lilly, replication by different investigators and funders (R2) is not confirmed, so the axis 2 R1 ceiling of B applies with 72 points; the axis 3 ceiling for manufacturer funding is not applied under the large hard-endpoint prescription-drug RCT exception
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of major adverse cardiovascular events in higher-risk type 2 diabetes | A | Direct MACE was significantly reduced with HR 0.88 in the 9,901-participant REWIND trial. |
| HbA1c lowering in type 2 diabetes | A | AWARD trials and long-term REWIND data consistently showed lowering across doses and background therapies. |
| Weight reduction | C | This was a consistent secondary effect, but it was a secondary endpoint in manufacturer development trials and not the core endpoint of the combined claim, so it is separately limited to C. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gerstein HC et al.; REWIND Investigators. 2019 | Multinational multicentre randomized double-blind placebo-controlled cardiovascular outcomes trial | 4 | Funded by Eli Lilly and Company | First composite MACE of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death | 594 of 4,949 versus 663 of 4,952 participants; HR 0.88 (95% CI 0.79 to 0.99; P=0.026). | Key large direct hard-endpoint evidence |
| Giorgino F et al. AWARD-2. 2015 | Seventy-eight-week randomized active-controlled trial | 810 | Eli Lilly development trial with company employees among the authors | Change in HbA1c plus hypoglycaemia, weight, and gastrointestinal adverse events | Once-weekly dulaglutide 1.5 mg produced greater HbA1c reduction than insulin glargine without forced titration. | Direct randomized active-controlled HbA1c evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-11 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-08-11 · Grade correction for unmet independent-replication requirement — The two cited papers, REWIND (NCT01394952) and AWARD-2 (NCT01075282), are separate trials but both were funded by Eli Lilly, and REWIND is the only trial testing the core MACE-reduction claim. Chamgap's A requires axis 2 R2 (multiple RCTs by different investigators and funders); while HbA1c RCTs are numerous, no independently funded placebo-controlled RCT other than REWIND has retested dulaglutide's MACE reduction. Axis 2 is R1 and the ceiling is B. The axes were recorded as B-H-R1-I0-E+-B1 with 72 points, the axis 3 ceiling for manufacturer funding not applied under the large hard-endpoint prescription-drug RCT exception. The effect itself (MACE HR 0.88, 95% CI 0.79 to 0.99, P=0.026, and HbA1c lowering) is not denied. Confirmed in the 2026-08-11 internal audit (workflow verification with concurring Codex cross-check). (grade A→B)
Cite this verdict
[Chamgap] Dulaglutide x lower HbA1c and reduce MACE in type 2 diabetes — Evidence Grade B·72. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/dulaglutide-type-2-diabetes-hba1c-mace/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.